In Med Pharmaceuticals Inc. INM
We take great care to ensure that the data presented and summarized in this overview for InMed Pharmaceuticals Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding INM
View all-
Sabby Management, LLC Upper Saddle River, NJ307KShares$86,0265.39% of portfolio
-
Virtu Financial LLC New York, NY86.7KShares$24,2710.0% of portfolio
-
Baader Bank Aktiengesellschaft Unterschleissheim, 2M22.6KShares$6,3310.0% of portfolio
-
Xtx Topco LTD London, X017.8KShares$4,9890.0% of portfolio
-
Hrt Financial LP New York, NY16KShares$4,4780.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il12.1KShares$3,3870.0% of portfolio
-
Qube Research & Technologies LTD London, X0200Shares$560.0% of portfolio
-
Bank Of America Corp Charlotte, NC100Shares$280.0% of portfolio
-
Td Waterhouse Canada Inc. Toronto, A685Shares$230.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ32Shares$80.0% of portfolio
Latest Institutional Activity in INM
Top Purchases
Top Sells
About INM
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Insider Transactions at INM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 31
2024
|
Alexandra Diane Janet Mancini |
SELL
Open market or private sale
|
Direct |
240
-100.0%
|
$0
$0.18 P/Share
|
|
Feb 21
2024
|
Andrew Hull Director |
BUY
Open market or private purchase
|
Direct |
37,500
+49.5%
|
$0
$0.39 P/Share
|
|
Feb 20
2024
|
Eric A Adams President & CEO |
BUY
Open market or private purchase
|
Direct |
41,600
+48.62%
|
$0
$0.36 P/Share
|
|
Apr 14
2022
|
Eric A Adams President & CEO |
BUY
Open market or private purchase
|
Direct |
14,160
+19.35%
|
$0
$0.89 P/Share
|
|
Apr 13
2022
|
Eric A Adams President & CEO |
BUY
Open market or private purchase
|
Direct |
8,560
+16.03%
|
$0
$0.85 P/Share
|
|
Jan 24
2022
|
Bruce Colwill CFO |
BUY
Open market or private purchase
|
Direct |
5,000
+30.28%
|
$5,000
$1.09 P/Share
|
|
Jan 06
2022
|
Shane Aaron Johnson Sr VP & General Manager |
BUY
Open market or private purchase
|
Direct |
8,500
+2.71%
|
$8,500
$1.26 P/Share
|
|
Dec 30
2021
|
Shane Aaron Johnson Sr VP & General Manager |
BUY
Open market or private purchase
|
Direct |
8,093
+2.66%
|
$8,093
$1.33 P/Share
|
|
Nov 15
2021
|
Shane Aaron Johnson Sr VP & General Manager |
BUY
Open market or private purchase
|
Direct |
5,000
+1.71%
|
$5,000
$1.37 P/Share
|
|
Sep 29
2021
|
Eric A Adams President & CEO |
BUY
Open market or private purchase
|
Direct |
8,800
+19.52%
|
$8,800
$1.73 P/Share
|
|
Sep 28
2021
|
Bruce Colwill CFO |
BUY
Open market or private purchase
|
Direct |
5,000
+43.42%
|
$5,000
$1.77 P/Share
|
|
Sep 28
2021
|
Eric A Adams President & CEO |
BUY
Open market or private purchase
|
Direct |
11,400
+29.32%
|
$11,400
$1.75 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 79.1K shares |
|---|
| Open market or private sale | 240 shares |
|---|